DiamiR

DiamiR is a privately held molecular diagnostics company developing blood-based solutions for early detection and monitoring of brain health and other conditions. DiamiR’s proprietary platform technology is based on the targeted, quantitative analysis of organ-enriched microRNA biomarkers circulating in plasma. Our first product, in late stage development, is CogniMIR for the early detection of synaptic loss and neurodegeneration in mild cognitive impairment and prediction of Alzheimer’s disease progression. CogniMIR combines brain-enriched and inflammation-associated microRNAs with an algorithm classifier. The market for CogniMIR is estimated at $850M in the U.S. and $2.6B globally. DiamiR collaborates with leading academic centers, disease foundations, and pharma companies. DiamiR owns worldwide rights to its technology and product candidates, including over 30 patents, comprising three patent families, issued since 2014, and four additional families in prosecution worldwide.